Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Global HIV Infection Drug Market & Pipeline Insight
Publication Date Aug 2014
Publisher KuicK Research
Product Type Report
Pages 1350
Single User License help $ 2400.00
Site User License help $ 4200.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.5 in 2013, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years. The access to these drugs and therapy has improved significantly, particularly in many developing countries where these drugs and treatments were previously not available at all. At present these solutions have been made accessible and affordable also.

However, a major trend observed in this market has been that although the HIV infection rates are falling, the number of new patients being affected by the virus is increasing.  With all the conscious efforts undertaken by all the related organizations and stakeholders, it is expected that by 2015, significant investments would be recorded in this field with the WHO setting an aim to treat close to 15 million HIV patients.

In terms of the market, with the rising popularity of this disease and the growing efforts to combat its spread, it is most likely that an increasing number of companies would enter this market, which would, in the long run, reduce the overall cost of drugs owing to increased competition among the players. Additionally, economies of scale would also be a major factor driving down the cost of drugs targeted for the HIV virus infected people. This in turn would make the drugs and treatment options more affordable.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

“Global HIV Infection Drug Market & Pipeline Insight” Report Highlight:

• Global HIV Infection Drug Market Overview & Incidence Scenario
• FDA & EMA Regulation for Development of HIV Drug
• Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
• Global HIV Clinical Pipeline: 315 Drugs in Development Phases
• Majority HIV Drug in Preclinical Phase: 144 Drugs
• Marketed HIV Drugs: 37
• Suspended & Discounted HIV Drug in  Clinical Pipeline: 539 Drugs
• Patent Analysis: Patent Number & Technology

1. Global HIV Infection Drug Market Overview
  1.1 Global HIV Incidence Scenario
  1.2 Market Overview: Global & Regional
  1.3 Clinical Pipeline Overview

2. Global HIV Infection Drug Market Dynamics
  2.1 Favorable Market Drivers
  2.2 Market Challenges to be Resolved
  2.3 Future Opportunity Outlook

3. FDA Regulatory Framework for Development of HIV Vaccine
  3.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations
  3.2 Guidance for Submitting HIV Resistance Data
  3.3 HIV Resistance Testing in Antiretroviral Drug Development
  3.4 HIV-1 Infection: Developing Antiretroviral Drugs for Treatment

4. EMA Regulatory Framework for Development of Medicinal Products For Treatment Of HIV Infection

5. Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
  5.1 Phase Unknown
  5.2 Research
   5.3 Preclinical
  5.4 Clinical
  5.5 Phase-0
  5.6 Phase-I
  5.7 Phase-I/II
  5.8 Phase-II
  5.9 Phase-III
  5.10 Preregistration
  5.11 Registered

6. Marketed HIV Drug Clinical Profile by Company & Country

7. Suspended & Discontinued HIV Drugs in Clinical Pipeline by Phase, Company & Country
  7.1 No Development Reported
  7.2 Discontinued
  7.3 Suspended

8. Competitive Landscape
  8.1 Antigen Express
  8.2 Bionor Pharma
  8.3 FIT Biotech
  8.4 Gilead Sciences
  8.5 GeoVax
  8.6 GenVec
  8.7 Glaxo Smithkline
  8.8 Immune Response BioPharma
  8.9 Inovio Pharmaceuticals
  8.10 Novartis
  8.11 Sanofi Pasteur

Figure 1-1: People Living With HIV Infection (Million), 2009-2014
Figure 1-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 1-3: People Living With HIV Infection by Region (%), 2012
Figure 1-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
Figure 1-5: Global - HIV/AIDS Therapeutics Market (US$ Billion), 2013-2018
Figure 1-6: Global - HIV Infection Drug Pipeline by Phase (%), 2014
Figure 1-7: Global - HIV Infection Drug Pipeline by Phase (Number), 2014
Figure 1-8: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (%), 2014
Figure 1-9: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (Number), 2014
Figure 1-10: Global – Discontinued HIV Infection Drug in Pipeline by Phase (%), 2014
Figure 1-11: Global – Discontinued HIV Infection Drug in Pipeline by Phase (%), 2014
Figure 1-12: Global – Suspended HIV Infection Drug in Pipeline by Phase (%), 2014
Figure 1-13: Global – Suspended HIV Infection Drug in Pipeline by Phase (%), 2014

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Abdominal Obesity-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abdominal Obesity-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establ ...Read More
$1250.00
Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abortion-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abscess-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abscess-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the un ...Read More
$1250.00
Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and m ...Read More
$2000.00
Absence Seizure-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z